Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Almotriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B known ✓ | P28222 | 5/20 | 0.57 |
| ▸ | HTR1D known ✓ | P28221 | 5/20 | 0.57 |
| ▸ | HTR1F known ✓ | P30939 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 7/20 | 0.85 |
| ▸ | HTR2A | P28223 | 4/20 | 0.85 |
| ▸ | HTR2B | P41595 | 3/20 | 0.85 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.85 |
| ▸ | HTR5A | P47898 | 10/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | HTR7 | P34969 | 2/20 | 0.57 |
| ▸ | HTR1E | P28566 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 1/20 | 0.57 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Almotriptan SCHEMBL1848914 | 1.00 | HTR1A (0.85) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| Almotriptan SCHEMBL2259962 | 1.00 | HTR1A (0.85) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| Almotriptan SCHEMBL1774275 | 0.93 | HTR1A (0.90) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| Almotriptan SCHEMBL1957 | 0.92 | HTR1A (1.00) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| Almotriptan SCHEMBL29396422 | 0.92 | HTR1A (1.00) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| Almotriptan SCHEMBL3273179 | 0.92 | HTR1A (1.00) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| Almotriptan SCHEMBL2761861 | 0.91 | HTR1A (0.86) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| SCHEMBL1437 | 0.91 | HTR1A (0.98) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| Almotriptan SCHEMBL2166 | 0.91 | HTR1A (0.98) | HTR1AHTR2AHTR2BADRA2BLMNA | |
| Almotriptan SCHEMBL5042399 | 0.90 | HTR1A (0.96) | HTR1AHTR2AHTR2BADRA2BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 519 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20200306463-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS ANDOR OBESITY | APTARGROUP, INC. | 2020-10-01 | — | — | US | claimed |
| US-20180200220-A1 | PROPHYLAXIS AND MITIGATION OF MIGRAINE HEADACHES USING KETOGENIC MEDIUM CHAIN TRIGLYCERIDES, KETONE ESTERS, AND OTHER KETOGENIC SOURCES | ULTIMATE BRAIN NUTRIENTS, LLC | 2018-07-19 | — | — | US | claimed |
| EP-3322427-A1 | PROPHYLAXIS AND MITIGATION OF MIGRAINE HEADACHES USING MEDIUM CHAIN TRIGLYCERIDES, KETONE ESTERS, AND OTHER KETOGENIC SOURCES | Cognate Nutritionals, Inc. (US) | 2018-05-23 | — | — | EP | claimed |
| US-20170304388-A1 | NEW INDICATION OF CARDIOVASCULAR DRUGS FOR PREPARATION OF CANCER INHIBITION PHARMACEUTICAL COMPOSITION | LAUNX BIOMEDICAL CO., LTD. (TW) | 2017-10-26 | — | — | US | claimed |
| WO-2017161387-A1 | COMPOSITIONS OF NATURAL EXTRACTS AND USE THEREOF IN METHODS FOR PREVENTING OR TREATING DISEASES | REID CHRISTOPHER BRIAN (US) | 2017-09-21 | — | — | WO | claimed |
| WO-2017011294-A1 | PROPHYLAXIS AND MITIGATION OF MIGRAINE HEADACHES USING MEDIUM CHAIN TRIGLYCERIDES, KETONE ESTERS, AND OTHER KETOGENIC SOURCES | COGNATE NUTRITIONALS, INC. (US) | 2017-01-19 | — | — | WO | claimed |
| US-20140271923-A1 | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions | REID CHRISTOPHER BRIAN (US) | 2014-09-18 | — | — | US | claimed |
| WO-2014130581-A1 | ACTH FOR TREATMENT OF MIGRAINE HEADACHE | QUESTCOR PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | WO | claimed |
| WO-2012085723-A1 | A PROCESS FOR THE PURIFICATION OF ALMOTRIPTAN ACID ADDITION SALT | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2012-06-28 | — | — | WO | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622971-B2 | Linear polysaccharide based film products | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260041775-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260041699-A1 | FOSPROPOFOL FORMULATIONS | EPALEX CORP (US) | 2026-02-12 | — | — | US | disclosed |
| WO-2004073632-A2 | RAPID ABSORPTION SELECTIVE 5-HT AGONIST FORMULATIONS | BIOVAIL LABORATORIES INC. (BB) | 2004-09-02 | — | — | WO | disclosed |
| US-20040162333-A1 | Rapid absorption selective 5-HT agonist formulations | BIOVAIL LABORATORIES INCORPORATED (BB) | 2004-08-19 | — | — | US | disclosed |
| US-20030225002-A1 | Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030196929-A1 | Pharmaceutical kit for migraine headache treatment | GOPINATHAN GOVINDAN (US) | 2003-10-23 | — | — | US | disclosed |
| WO-2003072138-A1 | CO-THERAPY FOR THE TREATMENT OF MIGRAINE COMPRISING ANTICONVULSANT DERIVATIVES AND ANTI-MIGRAINE AGENTS | ORTHO-MCNEIL PHARMACEUTICAL INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306463-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS ANDOR OBESITY | GABRQ, RPTOR, GABRG2 | HTR1B 676/4885HTR1D 1359/4885HTR1F 2641/4885 |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | CACNG6, MC5R, CRH | HTR1B 103/4885HTR1D 133/4885HTR1F 310/4885 |
| US-20030225002-A1 | Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents | HNMT, CNR2, GABBR1 | HTR1B 481/4885HTR1D 859/4885HTR1F 884/4885 |
| US-20260041699-A1 | FOSPROPOFOL FORMULATIONS | FOS, PSEN1, FDPS | HTR1B 3164/4885HTR1D 2537/4885HTR1F 2456/4885 |
| US-20260041775-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | SLC2A8, SLC5A2, SLC2A4 | HTR1B 87/4885HTR1D 213/4885HTR1F 506/4885 |
| US-12622971-B2 | Linear polysaccharide based film products | SORD, SMCHD1, PLEC | HTR1B 2221/4885HTR1D 1278/4885HTR1F 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.